4.7 Article

NIR-II Regulation of Mitochondrial Potassium Channel with Dual-Targeted Conjugated Oligomer Nanoparticles for Efficient Cancer Theranostics In Vivo

期刊

ADVANCED HEALTHCARE MATERIALS
卷 -, 期 -, 页码 -

出版社

WILEY
DOI: 10.1002/adhm.202301954

关键词

cancer therapy; conjugated oligomers; ion channels; mitochondrial DNA; near-infrared II

向作者/读者索取更多资源

This study develops a biomimetic nanoparticle with dual-targeted properties, allowing precise modulation of ion channels at the organelle level and selective killing of malignant tumor cells.
Cell fate can be efficiently modulated by switching ion channels. However, the precise regulation of ion channels in cells, especially in specific organelles, remains challenging. Herein, biomimetic second near-infrared (NIR-II) responsive conjugated oligomer nanoparticles with dual-targeted properties are designed and prepared to modulate the ion channels of mitochondria to selectively kill malignant cells in vivo. Upon 1060 nm laser irradiation, the mitochondria-located nanoparticles photothermally release a specific ion inhibitor of the potassium channel via a temperature-sensitive liposome, thus altering the redox balance and pathways of mitochondria. NIR-II responsive nanoparticles can effectively regulate the potassium channels of mitochondria and fully suppress tumor growth. This work provides a new modality based on the NIR-II nanoplatform to regulate ion channels in specific organelles and proposes an effective therapeutic mechanism for malignant tumors. A dual-targeted conjugated oligomer biomimetic nanoparticle with near-infrared II (NIR-II) response is developed to precisely modulate ion channels at the organelle level, and efficiently monitor organelle functions for fine regulation of cell fate. This nanoparticle can disrupt the redox balance and achieve selective therapy of chemically resistant malignant tumor cells in a noninvasive and biological manner.image

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据